June 2025– date –
-
Oncology Drug Approval News Flash: Mitomycin (Zusduri) Approved by FDA for Recurrent Low-Grade Intermediate-Risk NMIBC
【FDA Approval Alert】UroGen Pharma's mitomycin (Zusduri) Approved for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (June 12, 2025) On June 12, 2025, the U.S. FDA approved mitomycin (Zusduri) for adult patient... -
Oncology Drug Approval News Flash: Taletrectinib (Ibtrozi) Approved by FDA for ROS1-Positive NSCLC
【FDA Approval Alert】Nuvation Bio's taletrectinib (Ibtrozi) Approved for ROS1-Positive Non-Small Cell Lung Cancer (June 11, 2025) On June 11, 2025, the U.S. FDA approved taletrectinib (Ibtrozi) for adult patients with locally advanced o... -
Oncology Drug Approval News Flash: Darolutamide (Nubeqa) Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer
【FDA Approval Alert】Bayer's darolutamide (Nubeqa) Approved for Metastatic Castration-Sensitive Prostate Cancer (June 3, 2025) On June 3, 2025, the U.S. FDA approved darolutamide (Nubeqa) for metastatic castration-sensitive prostate can...
